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Background: The patient perspective is increasingly considered in healthcare policy decisions. The use of research
on patient preferences seems however limited. Using the available research on patient preferences would make
healthcare policy decisions more evidence-based regarding the patient perspective. Objective of this study is to
investigate whether and how results of research on patient preferences are incorporated in current procedures for
pharmaceutical coverage decisions and clinical practice guideline (CPG) development.
Methods: A document analysis on procedure descriptions was combined with case studies. Analyses were
performed for five European countries. In the document analysis we systematically checked whether the procedure
provides guidance on the systematic use of research on patient preferences, and whether the search and use of
research on patient preferences is mentioned in the decision making procedure. In the case studies, which were for
exploratory purposes, we scored whether or not research question on patient preferences were formulated,
whether or not a search strategy including terms relating to patient preferences was mentioned, whether results of
this search strategy were shown and finally, how many references with preference-related terms were included in
the reference list of the case.
Results: None of the procedures for pharmaceutical coverage decisions mentions the systematic consideration of
research on patient preferences. For CPG development, the Scottish procedure refers to a mandatory literature
search. In the Netherlands this step is optional. In the case studies for pharmaceutical coverage decisions only one
reference related to patient preferences was found. Some of the case studies for CPG included research questions,
search strategies and references relating to patient preferences.
Conclusions: This study illustrates that systematic consideration of research on patient preferences in
pharmaceutical coverage decisions and guideline development is limited, or if taken into account, this is not visible.
This contrasts the strong movement towards patient involvement in health care. Several potential barriers may
explain the limited use of research on patient preferences.
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There is an increasing body of empirical research on pa-
tient preferences towards health care and healthcare
outcomes [1]. However, the use of this research in
healthcare policy decision making seems limited [2-5].
Much of the literature on the importance of incorporating
the patient perspective in healthcare policy decisions fo-
cuses on direct, active participation (e.g. membership of
committees) [6]. However, it is questioned whether active
participation is the best way of incorporating the patient
perspective into healthcare policy decisions [7]. Using
research on patient preferences is another way for incorp-
orating the patient perspective in healthcare policy deci-
sions, which may contribute to the evidence-base of active
patient participation [7,8]. This article contributes to the
literature on incorporating the patient perspective in
healthcare policy decisions by focusing on the use of re-
search on patient preferences. In this paper we focus on
two types of decisions: pharmaceutical coverage decisions
(i.e. uptake of removal of a pharmaceutical in the benefit
package) and clinical practice guideline (CPG) develop-
ment. Integration of research evidence on patient prefer-
ences in pharmaceutical coverage decisions and CPG is
important for several reasons. A first argument is that re-
search evidence on patient preferences adds to other
knowledge bases and is therefore important for decision
making. Both pharmaceutical coverage decisions and CPG
are – at least in part – evidence-based and informed by
research on safety, effectiveness and/or cost-effectiveness.
Likewise, using the available research on patient pre-
ferences would make healthcare policy-making more
evidence-based with regard to the patient perspective. In
addition, studies on patient preferences may report on the
relative value of outcomes and experiences, which is not
covered by most patient reported outcomes and expe-
rience measures used in clinical studies. Further, incorpo-
ration of research on patient preferences may foster more
patient-centeredness of health care in general [6], and
even so on the individual level (shared decision making).
Finally, when constructing quality adjusted life years
(QALYs), the general public’s valuation is used for pa-
tients’ health states. As patient preferences may differ from
preferences of the general public, the patient perspective
gets short shrift. Second argument is that research evi-
dence on patient preferences may serve as a source of in-
formation for patient representatives in healthcare
decision making (empowerment) and provide what repre-
sentatives bring to the table with more scientific founda-
tion. A final argument is that patient preferences, amongst
others, are known to influence the cost-effectiveness of
healthcare services [9]. Furthermore, currently CPG do
not always reflect patients’ preferences [10] which causes
low adherence to and low acceptability of guidelines
[11]. Thus, consideration of research evidence patientpreferences in healthcare decision making may improve
the quality of decisions and yield return on investment on
research on patient preferences.
This paper describes the first step of the Patient-VIP
study (Patient Values In Policy making) [12], which is an
explorative study on the integration of research on pa-
tient preferences in pharmaceutical coverage decisions
and CPG. In three sub studies the Patient-VIP study
aims to develop a decision framework for the integration
of evidence on patient preferences in pharmaceutical
coverage decisions and CPG. The objective of the
current paper is to explore whether and how such re-
search is incorporated in coverage decision procedures
and CPG development. We applied a two-step analysis
for this study. First we studied the written guidance for
pharmaceutical coverage decisions and CPG develop-
ment for their content on using research on patient pre-
ferences (theoretical perspective). Second we studied
specific cases of pharmaceutical coverage decisions and
CPGs in order to explore if results of research on patient
preferences were considered (practical perspective). We
performed both steps for five European countries,
namely the Netherlands, England & Wales, Scotland,
Germany and France. We choose the Netherlands because
it is the origin of the Patient-VIP study. England & Wales,
Scotland (as representatives of the United Kingdom),
Germany and France were chosen because they are neigh-
bour countries of the Netherlands and the three largest
economies in Europe. We also choose these countries be-
cause of relevant differences with respect to the funding
system of the healthcare system (tax-funded in England &
Wales and Scotland versus social insurance-based in
France, the Netherlands and Germany). In addition, the
chosen countries have leading organisations in guideline
development, which will ascertain the availability of li-
terature. Studying the integration of evidence on patient
preferences in different countries will reveal similarities
and/or differences between countries, which provide
valuable information when working towards systematic in-
tegration of evidence on patient preferences in pharma-
ceutical coverage decisions and CPG.
Methods
Terminology
Preferences usually refer to the desirability of something
or someone [5]. There are several definitions of the term
‘preference’ used in different fields [5]. However, the
terminology used for preferences is not unambiguous
[3,13]. In the healthcare literature several related terms
are used when referring to preferences for healthcare
services or outcomes. These terms include patient per-
spective [13,14], value, utility [5,7], well-being, per-
ception [13], expectations [3-5,7,14], satisfaction [3,7],
experience [4,7,13], goals [3,14], concerns [5], desires [5],
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In the first step written guidance documents for phar-
maceutical coverage decisions and CPG development
were studied for their content on consideration of re-
search on patient preferences. Aim was to demonstrate
whether and how existing research on patient preferen-
ces is incorporated in current procedures for phar-
maceutical coverage decisions and CPG development.
Documents describing these procedures can be con-
sidered as grey literature, as they most likely will not be
found through searches in literature databases, like
PubMed. Therefore, literature and documents describing
current procedures of pharmaceutical coverage decisions
and CPG development were identified through internet
searches on the websites of the responsible national and
international organisations or institutes. Additional file 1:
Table S1 lists the organisations of which the websites have
been searched. In addition, reference lists of retrieved doc-
uments were hand searched for additional information on
the procedures. The references that were searched are
listed in Additional file 2. In the guidance documents we
systematically checked: 1) whether the procedure provides
guidance on the systematic consideration of research on
patient preferences; and 2) whether the search for and use
of research on patient preferences is mentioned in the de-
cision making procedure.
Case studies
We studied two pharmaceutical coverage decisions and
two CPG for each country in order to explore whether
research on patient preferences was considered. The
case studies are labour intensive. Because this study is
exploratory, we limited the number of case studies to
two per type of decision-making. With two case studies
it is still possible to see whether the results are similar
or deviating. In general, the cases were selected after a
discussion of the authors which revealed that for these
cases multiple treatment options are available, and pa-
tients’ could have preferences for either option.
The pharmaceutical coverage decisions chosen were bi-
ologicals for treating rheumatoid arthritis (available for all
five countries) [15-20] and pemetrexed for the first-line
treatment of non-small-cell lung cancer (not available for
Germany) [21-24]. This was also a pragmatic choice as it
turned out to be difficult to find matching pharmaceutical
coverage decisions for all countries.
For the case studies for CPG we were able to identify
matching and representative guidelines for all counties ononly one topic: rheumatoid arthritis [25-29]. The second
case study for each country differed between the countries
and were the treatment of prostate carcinoma for the
Netherlands [30], treatment of generalised anxiety disorder
for England & Wales [31], treatment of congestive heart
failure for Scotland and France [32,33] and treatment of de-
pression for Germany [34]. These guidelines were selected
because a PubMed search showed that research on patient
preferences was published at the moment of development.
The general and country-specific search was performed by
combining the different terms relating to ‘preference’ with
the guideline topic. For each guideline and coverage deci-
sion we searched if and how evidence on patient prefe-
rences was used by: 1) checking whether or not research/
scoping questions on patient preferences were formulated;
2) checking if a search strategy was mentioned including
terms related to patient preferences; 3) investigating
whether the results of the search strategy were displayed; 4)
scoring how many reference titles of the reference list in-
cluded terms that related to patient preferences; and for
pharmaceutical coverage decisions 5) whether the decision
text holds information relating to research on patient pre-
ferences”. The terms searched for and scored were derived
from previous studies, see above. Additional terms were
discussed between the authors.
Member check
A member check on the results of the document analysis
with representatives of the organisations involved in the
procedures was performed in order to assure that we in-
cluded all relevant documents and whether we interpreted
the documents correctly. We sent representatives the
paper by mail and asked for their comments. In total we
approached 14 persons and received six reactions. These
reactions concerned the coverage decision procedures in
the Netherlands, England & Wales, Scotland and Germany
and the CPG development procedures of England &
Wales, Scotland and Germany. The member check re-
vealed additional literature on recent developments in
Germany’s pharmaceutical coverage decisions. The mem-
ber check for Dutch pharmaceutical coverage decisions re-
quired only small changes in the procedure description
and not in the interpretation of the documents. The mem-
ber check on German CPG pointed out additional infor-
mation which was incorporated in this contribution. The
other member checks did not result in additional literature
and our interpretation was correct. Overall, the member
check did not alter our conclusions.
Results
Pharmaceutical coverage decisions –documents analysis
on procedure and patient preferences
Additional file 3: Table S2 provides an overview of the or-
ganisations involved in pharmaceutical coverage decisions
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mentions the systematic search for and use of research on
patient preferences, but the guidance documents leave
room for optionally using preference-related aspects. In
the Netherlands the procedure mentions that “in a wider
consideration of effectiveness, aspects like … quality of life
are discussed” (p. 37) [35]. The Dutch procedure also
mentions that “softer end-points like quality of life, patient
satisfaction and experiences of patients .... are considered
in the review” (p. 11) [36]. In England & Wales, quality of
life is an outcome measure used for the appraisal (p. 14).
In England & Wales, patient and carer groups can make
evidence submissions which may provide perspectives
from patients on experiences, preferences and expecta-
tions (p. 23) [37]. The procedure states that “standard
qualitative research techniques, such as thematic analysis,
facilitate the synthesis of evidence of this type. Accounts
and experiences may be collected and analysed syste-
matically using these qualitative research techniques, but
there is no requirement to present the information in
this way” (p. 23) [37]. In Scotland, patient interest groups
can make information submissions, which may include
“patient views on treatments and medicines” (p. 1) and
“preferences” (p. 1) [38]. The scientific requirements for
this information are not further stated. The procedure in
Germany mentions that “legal requirements specify in-
clusion of the following benefit parameters in the assess-
ment: .... improvement in the quality of life” (p. 518) [39].
This is to be defined in the scoping prior to the assess-
ment. The economic evaluations of England & Wales,
Scotland and the Netherlands include QALYs as an out-
come, which are based on population preferences for
quality of life outcomes [38,40,41]. As population values
may differ from patient values this was not considered as
fulfilling our inclusion criteria for research on patient pref-
erences. The French and German procedures do not men-
tion QALYs, neither based on patient, nor on population
preferences for health outcomes [41].
Clinical practice guidelines- documents analysis on
procedure and patient preferences
The different procedures of CPG development can be
found in Additional file 4: Table S3.
The development procedure in Scotland mentions “a lit-
erature search strategy to identify both qualitative and
quantitative studies that reflect patients’ experiences and
preferences in relation to the clinical topic” (p. 19) that is
mandatory and should take place before the first meeting
of the working committee [42]. In the Netherlands this is
an optional step: “literature search into the patient per-
spective … is recommended to be performed prior to the
guideline development” (p. 7) [43]. Furthermore, the
Dutch procedures also mention “specific literature search
to the needs and/or preferences of patients” (chapter 3.2)[44]. If findings from these studies are incorporated in
CPG, they are often reported as ‘other considerations’
right below the recommendations, or in a separate generic
chapter of the guideline. In the development procedure of
England & Wales “patient experience …should inform
development of a structured review question. In addition
review questions that focus on a specific element of pa-
tient experience may merit consideration in their own
right.” (p. 59) [45]. Consequently, if one of the review
questions is focused on patient preferences, a literature
search for evidence concerning the topic will be per-
formed. On what is exactly meant by patient experiences,
the guideline states: “Patient experience....covers a wide
range of dimensions, including: patient views on the ef-
fectiveness and acceptability of given interventions; patient
preferences for different treatment options and patient
views on what constitutes a desired, appropriate or accept-
able outcome”. (p. 65) [45]. The key role of patient and
carer members of guideline development groups in
England & Wales is “raising awareness of grey literature
known to them (for example patient surveys) that high-
lights patient issues…” (p. 46) [45]. The guideline deve-
lopment group in England & Wales is “encouraged to
actively search for qualitative research on patients’ views
and experiences…” (p. 20) [46]. The English/Welsh and
Scottish procedures also mention that patient groups and
local organisations are invited to submit evidence or infor-
mation on patient views [42,45]. The German procedure
does not mention the search for research on patient pref-
erences, but patient organisations are asked to work up
and document patient experiences and are provided with
tools to do so [personal communication from member
check CS]. The French procedures do not make any refe-
rence to the consideration of research on patient prefe-
rences [41].
Case studies
The first coverage decision studied was on biologicals for
rheumatoid arthritis and/or ankylosing spondylitis. None
of the pharmaceutical coverage decisions mentioned re-
search questions or a search strategy regarding patient
preferences. The Scottish and English/Welsh coverage de-
cision includes a reference with the term quality of life in
the title [15,16,24]. The texts of the Dutch, English/Welsh
and Scottish pharmaceutical coverage decisions include
passages referring to research findings on patients’ quality
of life [15,16,22]. The Dutch, English/Welsh and Scottish
documents report on QALYs based on population prefe-
rences for health outcomes [15,16,22-24]. In the Scottish
document it is stated that patient interest groups made a
submission, without providing details [16].
The second coverage decision studied was on peme-
trexed for non-small lung cancer. None of the pharma-
ceutical coverage decisions’ texts mentioned research
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ferences, nor did the reference lists include references
relating to research on patient preferences. In the
English/Welsh, Scottish and Dutch reports a reference is
made to a study that elicited population preferences for
health-related quality of life in lung cancer by a visual
analogue scale and a standard gamble technique inter-
view [17,19,20]. No reference to patient preferences for
health-related quality of life is made [17,19,20]. The
Dutch and French reports state that evidence on the
effects on quality of life are not available [17,19]. The
Scottish report mentions that a submission by a patient
interest group was received, but no details regarding this
submission are provided [20].
Table 1 shows the results for the two CPG case studies.
The use of research on patient preferences varied between
the guidelines and between countries. A research question
on patient preferences does not necessarily lead to higher
percentages of references with preference-related terms in
the guideline. Table 2 shows how many references were
found in the guidelines on rheumatoid arthritis, per term.
The terms that are mostly mentioned in the reference lists
are “(health related) quality of life”, “patient perspective”
and “well-being”. Table 2 shows how many references
were found in the guidelines that differed between the
countries. The terms that appeared most often were
“quality of life” and “needs for”.
Discussion
The results of this explorative study confirm our expec-
tation that systematic consideration of research on patient
preferences is limited in both pharmaceutical coverageTable 1 Results for the clinical practice guideline case studies
Rheumatoid arthritis
The Netherlands Englan
Were research questions set on patient
preferences?
No Yes
Was search strategy described? No No
Were results of search strategy summarised? No No
Number of references with preference-related
term in reference list (% of total number of
references)






Were research questions set on patient
preferences?
Yes Yes
Was search strategy described? No Yes
Were results of search strategy summarised? No No
Number of references with preference-related
term in reference list (% of total number of
references)
48 (5%) 26 (6%decisions and CPG (clinical practice guideline) develop-
ment, or if it is considered, this is not visible. This result is
more strongly present in pharmaceutical coverage deci-
sions than in CPG development. The coverage case stud-
ies showed that research on patient preferences were
mainly found in the documents text as research findings
on quality of life. The CPG guidance documents indicate
that the consideration of research on patient preferences
is optional (the Netherlands), not mandatory but encour-
aged (England & Wales) or completely absent (France and
Germany). Only the Scottish procedure explicitly men-
tions a “search for patient evidence”, which is executed be-
fore the start of the CPG development and is informative
for the development of review questions. Several CPG
cases reported research questions relating to patient pre-
ferences, for which a literature search was performed, in a
way comparable to other research questions. The case
studies on CPG showed several references with terms re-
lated to preferences. The terms most frequently used were
“quality of life”, “needs”, “perspective” and “well-being”.
The absence of instructions for the consideration of re-
sults of research on patient preferences in pharmaceutical
coverage decisions confirms the limited focus on this type
of research in health technology assessment [3]. In CPG
development the importance of incorporating research on
patient preferences is more acknowledged, as could be de-
rived from the results of the case studies. The GRADE
classification system for the strength of recommendations
in guidelines, holds that patient preferences, among
others, can affect the strength of recommendations [47].
Our results on the consideration of research on patient
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Value 0 0 0 0 0 0 0 0 0 0 0
Utilities 1 0 0 0 0 0 0 2 0 1 4
Preference 3 1 5 0 0 2 1 0 0 0 12
View 1 0 1 0 0 1 0 0 0 0 3
Goal 0 0 0 0 0 0 0 0 0 0 0
Belief 3 0 0 0 0 1 0 0 0 0 4
Expectation 0 0 0 0 0 0 0 0 0 0 0
Experience 2 0 5 0 0 2 0 0 0 0 9
Satisfaction 0 0 0 0 0 3 0 1 0 0 4
Health related
quality of life
3 1 3 0 1 9 0 2 2 1 22
Quality of life 4 3 18 0 3 4 0 2 0 1 35
Concern 0 1 2 0 0 0 0 0 0 0 3
Desire 0 0 0 0 0 0 0 0 0 0 0
Perspective 2 0 4 0 3 2 0 4 1 0 16
Attitude 0 0 0 0 1 0 0 0 0 0 1
Perception 1 1 0 0 0 1 0 0 0 0 3
Well being 1 1 1 0 1 4 0 1 1 1 11
Need (for) 5 0 9 0 4 2 0 0 0 0 20
Choice 0 0 0 0 0 2 0 0 0 1 3
PRO 0 0 0 0 0 1 0 0 0 3 4
GAD: generalised anxiety disorder; CA: carcinoma; RA: Rheumatoid Arthritis.
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tempt was made to use research on patient preferences [6].
The limited attention for the consideration of research
on patient preferences, especially in pharmaceutical cover-
age decisions, is in contrast with the strong movement to-
wards patient involvement in healthcare decision making.
This suggest that there may be barriers for the conside-
ration of research on patient preferences in pharmaceu-
tical coverage decisions and CPG development. Literature
mentions several barriers that have normative origin, con-
ceptual origins, methodological origins, procedural origin
and practical origin. Normative barrier is that HTA and
health economics community, the predominant measure
in economic evaluation is the Quality Adjusted Life Year
(QALY), which is determined by using preferences of a
general population for health states of patients. Brazier
et al. performed a review mentioning all positive, norma-
tive and methodological arguments both in favour and
against the use of patient preferences [48]. Arguments re-
late for example to the allocation of collective resources,
the foundations of welfare economics, as well as syste-
matic differences between public and patient values. Sec-
ond normative barrier is that the QALY is derived from
patient outcomes for quality of life related to health.However, patients may derive utility from aspects beyond
health, e.g. process or organisation of care, which is pur-
posely excluded from the QALY [49]. It should be deter-
mined whether society is willing to pay for the preferences
beyond health outcomes. If we decide to incorporate these
preferences, the methodological issues of the limitations
of the QALY should be addressed. Procedural barrier is
that the place of evidence on patient preferences in
pharmaceutical coverage decisions and CPG development
is not well determined. There is debate on the potential
benefits and downsides of the integration of evidence on
patient preferences. In the field of CPG development
some consider using research on patient preferences as an
unsubstantiated add on to already lengthy and complex
guidelines that may further decrease adherence, usability
and possibilities for transfer of knowledge into translate
into practice [50]. Some view patient preferences as funda-
mentally a property of the individual and question the
usefulness of aggregate preferences for individual decision
making [3,50]. Indeed, patient preferences can be very
heterogeneous. However, current decision making is also
informed by aggregate data on effectiveness and cost-
effectiveness. Aggregate data on patient preferences are
however not a substitute for elicitation of individual
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with their patients. Contrary, aggregate evidence on pa-
tient preferences may indicate that decisions are
preference-sensitive [3,5] which may stimulate clinicians
to help patients construct their individuel preferences. In
addition, research in general supports individual decision
making, as more information may reduce uncertainty.
Other procedural barrier is that the importance attached
to evidence on patient preferences is, purposely, not equal
to that placed on evidence on effectiveness and cost-
effectiveness [3,51]. It remains unclear whether this type
of evidence should get some weight in pharmaceutical
coverage decisions and guideline development, and how
this relates to other evidence.
Barrier of conceptual origin is that previous studies
showed that there is much variability in terminology
used for preferences [14]. This is confirmed in our study
in the procedures for guideline development and dem-
onstrated in the CPG case studies. We retrieved several
discussion papers on the subject of integration of patient
preferences in healthcare decision making, using a wide
spectrum of terms. In addition to the ambiguity in
terminology, there is heterogeneity in the type of study
design and measurement techniques that constitute
preference related research [3,13]. Furthermore, it is
stated that evidence on patient preferences is often of
low quality and shows variability in results [5]. It is
argued that the variability in terminology and different
measuring methods result in difficulties in the search for
these studies, the synthesis of evidence and the judge-
ment whether the results are valid for the purpose
of pharmaceutical coverage decisions and CPG. Some
authors argue that there is a lack on research on patient
preferences, which is considered a practical barrier
[50,51]. Indeed, at the time of pharmaceutical coverage
decisions are made research on patient preferences is
often not available. However, for CPG it is not clear
whether there is indeed an absolute lack on this type of
evidence or that the available research is not recognised
as such. Finally, a methodological barrier is that it is ar-
gued that there are no clear existing methods for incorp-
orating evidence on patient preferences in the decision-
or development process [51].
Before systematic integration of research on patient
preferences in the procedures of pharmaceutical cover-
age decisions and CPG development will succeed, the
previously described issues need to be addressed. The
lack of conceptual and methodological clarity in prefe-
rence research can be addressed by the development of
a conceptual map on preferences, incorporating all
contributions from all relevant disciplines and a taxo-
nomy to systematically categorise the different types of
research (and measurement techniques), as suggested by
Brooker et al. [13] and Chong et al. [3]. The proceduralissues need to be addressed by reaching consensus on
the place of patient preferences in decision making and
addressing possible barriers for integration. To address
both issues we currently undertake a qualitative study as
was prescribed in a previously published research proto-
col [12]. This qualitative study constitutes interviews
with relevant stakeholders in which the opinions and
ideas of relevant stakeholders with regard to the facilita-
tors and barriers for integrating research on patient pre-
ferences in pharmaceutical coverage decisions and CPG,
as well as the taxonomy for research on patient pre-
ferences values, will be addressed. The results of the
current study will be used as input for the qualitative
study and the subsequent development of a taxonomy
for research on patient preferences.
Our study has several limitations. We only studied
written documents for answering our research question
in this explorative study. Written guidance documents
provide guidance on how procedures should be executed
and the written pharmaceutical coverage decisions and
CPG are the result of the procedure that was followed.
We therefore considered them a reliable source of in-
formation. We acknowledge however that there may be
discrepancies between what is written down and the
practical execution that was not reported in the coverage
decision or CPG, as decision making can be seen as a
dynamic process which is sensitive to contextual factors.
Exploring this possible discrepancy requires other re-
search methodologies and was beyond the scope of this
paper.
Unfortunately, we did not receive a member check re-
sponse for both pharmaceutical coverage decisions and
CPG for all countries. As a result, we may have missed
valuable additional information. However, the responses
we did receive did not change our conclusions. We
therefore do not expect that additional responses would
have changed our conclusions.
Despite the member check, and although we have
thoroughly reviewed the national procedures of pharma-
ceutical coverage decisions and CPG development on
the integration of research values, it is possible that we
missed documents that may have included more infor-
mation on this subject. The number of case studies we
performed is not sufficient to draw firm conclusions.
Our results are at best indicative for current practice.,
The focus of our study was the use of results of research
on patient preferences (passive patient participation) and
not on other forms of (active) patient participation (e.g.
membership of CPG development group). In the mem-
ber check the confusion on the difference between active
participation and the consideration of research on pa-
tient preferences became clear. Indeed we do realise that
patient participation is a broad concept which has many
forms. Much is already known on active participation in
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ment and we intentionally focussed on the consideration
of research as little is known on this topic. However,
there is a grey area when defining research. Research
includes existing, secondary research, but it can be
debated whether it also includes results of primary re-
search (e.g. focus groups) performed for the purpose of
the specific coverage decision or guideline under deve-
lopment. Another limitation may be that although we
included a broad range of terms that referred to patient
preferences, this range may have been incomplete, and
we may have missed relevant terms. Nonetheless, this
would mean the variability in terms used to refer to pa-
tient preferences is even larger than presumed, it em-
phasises the need for more uniformity and transparency
in terminology.
Conclusions
In current written procedures for pharmaceutical coverage
decisions there does not seem to be room for the consi-
deration of research on patient preferences. In clinical
practice guidelines there is more attention for patient
preferences research, although not in a systematic man-
ner. We have listed several barriers that need to be
addressed before research on patient preferences can sys-
tematically be considered in pharmaceutical coverage de-
cisions and clinical practice guidelines. Future research
should elaborate more on the barriers and how to over-
come them. We have planned to do so in the upcoming
steps of the patient-VIP study.
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